Caris Life Sciences lifts US IPO price range
June 16 (Reuters) - Cancer diagnostic firm Caris Life Sciences said on Monday it was targeting a valuation of $5.67 billion in its U.S. initial public offering, after raising its proposed price range.
The Irving, Texas-based company is marketing the IPO at a price range between $19 and $20 apiece, according to a regulatory filing. It is seeking up to $470.6 million.
BofA Securities, J.P. Morgan, Goldman Sachs and Citigroup are the lead underwriters.
Caris will start trading on the Nasdaq on Wednesday under the symbol 'CAI'.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Nebius Stock: Can This AI Infrastructure Play Really Double in 2026?

Amazon 2026 Q1 Earnings Preview: AWS and Advertising Dual Engines Power Ahead, Can They Allay Market Doubts?

Google Bets $40B on Anthropic: Is Google Cloud the New Growth Engine as Meta Challenges Ad Dominance?

Intel Posts Best Day Since 1987 as Nvidia Market Cap Reclaims $5 Trillion: Is the AI Trade Overstretched?

Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Tradingkey







